SecBot SecBot
424B5 ·Filed Jun 8, 2026

IDYA

IDEAYA Biosciences, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed5mo ago SEC0001193125-26-261756
Notable filing: 424B5
Actionable Insight ▼ Bearish

The $300M offering is being conducted shortly after strong pipeline catalysts (ASCO data, Roche deal, NDA acceptance), suggesting the company is opportunistically raising capital at a premium to cash value. The immediate dilution pressure is the key near-term risk. Monitor the pricing of the offering relative to the $28.29 close on June 5, a discount greater than 5% would be particularly bearish. Watch for any insider participation as a mitigating signal.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.07
T+0 close · Jun 8, 2026 · via day close
Latest settled
+43.11%
T+60 · $40.17
Vs SPY
+39.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 9 $28.07entry
  2. T+1 · 5mo ago −1.67%α −0.10% · $27.60
  3. T+5 · 5mo ago +7.70%α +5.28% · $30.23
  4. T+20 · 4mo ago +44.32%α +42.87% · $40.51
  5. T+60 · 3mo ago +43.11%α +39.29% · $40.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre-funded warrants, with an additional $45M greenshoe option. The offering comes on the heels of positive Phase 2/3 data for darovasertib in uveal melanoma presented at ASCO on June 1, a newly announced Roche collaboration for IDE892 in pancreatic cancer, and an NDA acceptance for review under the FDA's Real-Time Oncology Review program. The massive dilution (~12%+ at current share count, more with warrants exercised) is the dominant near-term factor, offsetting the positive pipeline catalysts and potentially capping upside.

Key Facts

  • $300 million offering of common stock and pre-funded warrants
  • Underwriters have option to purchase up to an additional $45 million of common stock
  • Last reported stock price: $28.29 on June 5, 2026
  • Net tangible book value as of March 31, 2026: $937.3 million, or $10.67 per share
  • 87,856,154 shares outstanding as of March 31, 2026
  • Proceeds for continued clinical development and potential commercialization of darovasertib for uveal melanoma, advancement of pipeline, and general corporate purposes
  • Positive OptimUM-02 Phase 2/3 data presented June 1, 2026: darovasertib combination met primary endpoint with median PFS 6.9 months vs 3.1 months (HR: 0.42; p<0.0001)
  • FDA agreed to review NDA for darovasertib under Real-Time Oncology Review program in April 2026; NDA filing expected H2 2026
  • Roche clinical collaboration announced June 3, 2026 for IDE892 in MTAP-deleted pancreatic cancer

Financial Impact

$300M offering (plus up to $45M greenshoe) representing approximately 12-17% dilution to existing shareholders at the current ~88M share count, with additional dilution from pre-funded warrants

dilutionshare countnet tangible book value

Risk Factors

  • Immediate and substantial dilution to existing shareholders
  • Dilution could be 12-17%+ depending on exercise of greenshoe and pre-funded warrants
  • Proceeds use is at management's broad discretion with no specific M&A target identified
  • Biotech market volatility may amplify the share price impact of a large secondary
  • Pre-funded warrants have no public trading market and limited liquidity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-261756
Document: 0001193125-26-261756-index-headers.html0001193125-26-261756
Document: 0001193125-26-261756-index.html0001193125-26-261756
Document: 0001193125-26-261756.txt0001193125-26-261756

Track record

13 reports on IDYA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Viewing Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026